Overview
Updated 14 Jul 2026
Sundar Jagannath, MD, is Professor of Medicine (Hematology and Medical Oncology) at Icahn School of Medicine at Mount Sinai / Mount Sinai Tisch Cancer Center. The public record shows 1,113 publications with 63,181 citations (h-index 113), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 16 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 40 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 483.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Sponsor: Larysa Sanchez
InvestigatorPhase 2Active, not recruitingNCT04052880 - Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Sponsor: Sundar Jagannath
InvestigatorNo, longer, availableNCT02541643 - Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
Sponsor: Jagannath, Sundar, M.D.
InvestigatorPhase 2TerminatedNCT01096810
Industry payments
Updated 14 Jul 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments
- Janssen Global Services, LLCProgram year20251 payment
- Legend Biotech USA Inc.Program year20253 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
213 congress contributions (2004–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.
American journal of hematology
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03An inflammatory cytokine signature predicts COVID-19 severity and survival2,739 citations2020
- 04A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1 Gustave L. Levy Place, New York, NY 10029
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sharecare.com ↗ - Board Certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sharecare.com ↗
Editorial & leadership rolesjournal and society appointments
- Senior Editor-in-Chief
Clinical Lymphoma, Myeloma & Leukemia (journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - Board Member
International Myeloma Society
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - Board Member
Society of Hematologic Oncology (SOHO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Awards & honorshonors on the public record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
- Michaeli Lifetime Achievement Award for Outstanding Contributions to Multiple Myeloma
SASS-ARENA Foundation for Medical Research
2022provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Secondary affiliationsappointments beyond the home institution
- Scientific Advisory Board
Caribou Biosciences, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →investor.cariboubio.com ↗
Media & interviewspress, podcasts and appearances
- Video interview library
VJHemOnc speaker profile featuring multiple recorded interviews on multiple myeloma research/treatment
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - Bio and patient-education video content
Patient Power
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- ResearchGate
researchgate.net/profile/Sundar-Jagannath
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/sundar-jagannath-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jagannath-sundar-20b8aba4
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- X / Twitter
x.com/Myeloma_Society/status/1707322267103813904
- X / Twitter
x.com/TischCancer/status/1790829719392281057
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Boston University
- 3,069
- publications
- 199
- h-index
- 5
- trials
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
S Rajkumar, MD
WinnMed
- 1,861
- publications
- 166
- h-index
- 11
- trials
Meletios Dimopoulos, MD
Korea University
- 2,990
- publications
- 159
- h-index
- 13
- trials